AI-assisted tumor volumetric analysis in GBM.
Congratulations to Professor Bisdas (Head of IAG’s Neuro-Oncology Clinical Research), and colleagues for publishing this study that demonstrated that AI-assisted tumor volumetric analysis is a more sensitive way to distinguish between pseudo and true treatment response. The following abstract will be presented at the 26th Annual Conference for the Society of Neuro-Oncology in Boston on November 18-21, 2021.
The current standard of care for radiographically differentiating between pseudo and true disease progression in glioblastoma is currently using a 2D SPDP analytical approach called the modified radiographic response assessment in Neuro-Oncology (mRANO).
This methodology, however, carries several drawbacks, including sampling bias and irregular calculations regarding the shape of the tumor. Newer technology has created ways to evaluate the tumor in 3D while providing pivotal information about the tumor’s cell density, vascularity, and blood vessel leakage and diffusion. In this study, Dr. Bisdas et al compared these two methods using images from 8 of 45 patients with recurrent GBM who received an investigational Vivacitas Oncology drug, AR-67, in a phase 2 clinical study.
Volumetric analysis showed a mean response rate of +22% when compared to +17% using the SPDP (mRANO). SPDP overestimated the size of tumor tissue, which falsely underestimated the efficacy of the drug AR-67.
Overall, the findings from AI-assisted volumetric analysis increased our understanding of the drug’s therapeutic potential.
A recent interview and podcast with Dr. Bisdas, where he explains in depth the advanced 3D and chemical radiologic methods being used to quantify glioblastoma growth and regression.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin